Background and Objectives

Development of effective therapies for Parkinson's is a high risk and costly endeavor. Recently, a focus on data collected using new digital technologies has been introduced to improve the assessment of day-to-day experience of people living with Parkinson's. Worldwide collaborative initiatives are in place to take advantage of mobile sensors and devices as new tools to inform wide network and describe how all stakeholders are working together to advance the utility of digital technologies for use in Parkinson's trials.

Objective: To present CPP’s pre-competitive collaborative worldwide network and describe how all stakeholders are working together to advance the utility of digital technologies for use in Parkinson's trials.

Critical Path for Parkinson’s consortium

What is Important to you?

Scores, scales, markers, neurological examination etc. (things that your doctors use today)

TODAY: How do we measure what is important to you?

Better trials to test medications that positively impact what’s important to you

TOMORROW: How can we improve the way we measure what is important to you?

TECHNOLOGY:

E. Ray Dorsey

Arora et al., 2018

Conclusions

The information gathered from CPP’s assessment of the use of digital technology in Parkinson’s studies will apply learnings from other consortium initiatives to develop novel tools to improve Parkinson’s clinical trials. A robust collaboration between all stakeholders around the world centered on data standards and data sharing is key for success in the future.

References

(1) Stephenson et al., 2015; J. Parkinson’s Dis 5(3): S81–S94.
(2) FDA 2016 Parkinson’s Disease Voice of the Patient Report [Internet]. U.S. Food and Drug Administration; 2016 Apr.
(3) E. Ray Dorsey, 2018 unpublished
(4) Arora et al., 2016(4)

Acknowledgments: The Critical Path Institute’s Critical Path for Parkinson’s (CPP) Consortium is funded by Parkinson’s UK and the following industry members: AbbVie, Biogen, Denali, GSK, H. Lundbeck A/S, Merck Sharp and Dohme, F. Hoffmann La Roche, Sanofi Genzyme, IXICO, Takeda and UCB. We also acknowledge additional CPP member organizations, including Cure Parkinson’s Trust, Davis Phinney Foundation, Michael J. Fox Foundation, Newcastle University, Parkinson’s Foundation, Radboud University, University of Cambridge, University of Glasgow, University of Oxford, NNDS, FDA, and EMA. The authors acknowledge Ira Shoulson, Michele Hu, Maurizio Facheris, Ray Dorsey and Arthur Roach. [*Author current affiliation: Novartis]